Project Echo, Prader-Willi Syndrome Association | USA

ECHO 4 PWS: Sleep

When: Thursday, March14, 2024 at 6:00 p.m. EST
Where: Virtual/Zoom Video
This series is for healthcare providers only

Register for our next ECHO 4 PWS webinar, “Sleep with Dr. Amee Revana,” at the button below.

PWSA | USA's - ECHO 4 PWS Health Care Provider Series

PWSA | USA launched our new Health Care Provider Project ECHO Series, ECHO 4 PWS, in 2023. We are proud to offer this opportunity to health care professionals who work with patients affected by Prader-Willi syndrome (PWS) and to be the first PWS organization to implement Project ECHO® in the United States.

Our next healthcare ECHO topic will focus on Sleep and PWS presented by Amee Revana, DO FAASM, Associate Professor of Pediatrics, Texas Children’s Hospital, followed by a 20-minute case study on PWS (speaker to be determined).

PWSA | USA’s Health Care Provider Project ECHO Series will touch on a wide range of healthcare topics in the PWS space and will be available for all health professionals across our network including (but not limited to): Geneticists, Pediatric Endocrinologists, Neonatologists, Nurses, Pediatricians, Endocrinologists, Psychiatrists, Psychologists, Social Workers, Occupational Therapists, Pulmonologists, Orthopedic Surgeons, Dieticians, Physiotherapists, Speech and Language Therapists, Medical Students and Professional Caregivers.

While this ECHO series is only for health care providers to attend, recordings of the webinars are available for our PWS families to view HERE.

Be on the lookout for more details about future ECHO 4 PWS webinar opportunities.

Speaker

Amee Revana, Prader-Willi Syndrome Association | USA

Amee Revana, DO FAASM, Associate Professor of Pediatrics, Texas Children’s Hospital

Amee Revana, DO FAASM is an associate professor of pediatrics and is a triple board certified in general pediatrics, pediatric pulmonary and sleep medicine.  She cares for children at Texas Children’s Hospital in Houston, Texas.   She has a strong interest in medical education and research. 

LEarn More about PWS Research

Pitolisant Issued Orphan Drug Designation , Prader-Willi Syndrome Association | USA

Pitolisant Receives Orphan Drug Designation

Pitolisant from Harmony Biosciences Receives Orphan Drug Status from FDA for Treatment of PWS The FDA has granted Orphan Drug status to pitolisant, the trial drug from Harmony Biosciences to treat excessive daytime sleepiness (EDA) and behavioral disturbances. The designation shows that the FDA considers pitolisant to be a promising treatment for people with PWS.  […]

Wednesday January 26 2024 800 PM EST 3, Prader-Willi Syndrome Association | USA

Neuren Pharmaceuticals Opens Third Trial Site for Phase II PWS Study

Neuren Pharmaceuticals is pleased to announce their third site participating in their Phase II, Open Label, PWS Study (Neu-2591-PWS-001) is now open for screening! Important information regarding this exciting milestone: Three sites are now open to enrollment! Rare Disease Research (RDR), located in Atlanta, GA, and Uncommon Cures, located in Chevy Chase, MD (8 miles outside of Washington, D.C.) and […]

Wednesday January 26 2024 800 PM EST 3, Prader-Willi Syndrome Association | USA

Neuren Pharmaceuticals Opens Second Trial Site for Phase II PWS Study

Neuren Pharmaceuticals is pleased to announce their second site participating in their Phase II, Open Label, PWS Study (Neu-2591-PWS-001) is now open for screening! Important information regarding this exciting milestone: Two sites are now open to enrollment! Rare Disease Research (RDR), located in Atlanta, GA, and Uncommon Cures, located in Chevy Chase, MD (8 miles outside […]

Scroll to top